000			02230 a2200649 4500
005			20250514010807.0
264		0	_c20011011
008			200110s 0 0 eng d
022			_a0953-816X
024	7		_a10.1046/j.0953-816x.2001.01653.x _2doi
040			_aNLM _beng _cNLM
100	1		_aCrocker, S J
245	0	0	_aNAIP protects the nigrostriatal dopamine pathway in an intrastriatal 6-OHDA rat model of Parkinson's disease. _h[electronic resource]
260			_bThe European journal of neuroscience _cJul 2001
300			_a391-400 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAmphetamine _xpharmacology
650	0	4	_aAmyloid beta-Protein Precursor _xdrug effects
650	0	4	_aAnimals
650	0	4	_aAntibodies _xpharmacology
650	0	4	_aCaspase 3
650	0	4	_aCaspases _xdrug effects
650	0	4	_aCell Survival _xdrug effects
650	0	4	_aDNA Fragmentation _xdrug effects
650	0	4	_aDisease Models, Animal
650	0	4	_aDopamine _xmetabolism
650	0	4	_aFluorescent Dyes _xpharmacology
650	0	4	_aGenetic Vectors _xphysiology
650	0	4	_aImmunohistochemistry
650	0	4	_aMale
650	0	4	_aMovement Disorders _xdrug therapy
650	0	4	_aNeostriatum _xmetabolism
650	0	4	_aNerve Degeneration _xdrug therapy
650	0	4	_aNerve Tissue Proteins _xgenetics
650	0	4	_aNeural Pathways _xmetabolism
650	0	4	_aNeuronal Apoptosis-Inhibitory Protein
650	0	4	_aNeurotoxins _xpharmacology
650	0	4	_aOxidopamine _xpharmacology
650	0	4	_aParkinsonian Disorders _xdrug therapy
650	0	4	_aRats
650	0	4	_aRats, Wistar
650	0	4	_aSubstantia Nigra _xmetabolism
650	0	4	_aSympatholytics _xpharmacology
700	1		_aWigle, N
700	1		_aListon, P
700	1		_aThompson, C S
700	1		_aLee, C J
700	1		_aXu, D
700	1		_aRoy, S
700	1		_aNicholson, D W
700	1		_aPark, D S
700	1		_aMacKenzie, A
700	1		_aKorneluk, R G
700	1		_aRobertson, G S
773	0		_tThe European journal of neuroscience _gvol. 14 _gno. 2 _gp. 391-400
856	4	0	_uhttps://doi.org/10.1046/j.0953-816x.2001.01653.x _zAvailable from publisher's website
999			_c11475727 _d11475727